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Thyroid hormone (TH) plays an essential role in normal brain development and function.
Both TH excess and insufficiency during development lead to structural brain abnormalities.
Proper TH signaling is dependent on active transport of the prohormone thyroxine
(T4) across the blood-brain-barrier and into brain cells. In the brain T4 undergoes local
deiodination into the more active 3,3′,5-triiodothyronine (T3), which binds to nuclear TH
receptors (TRs). TRs are already expressed during the first trimester of pregnancy, even
before the fetal thyroid becomes functional. Throughout pregnancy, the fetus is largely
dependent on the maternal TH supply. Recent studies in mice have shown that normal
hypothalamic development requires intact TH signaling. In addition, the development
of the human lateral hypothalamic zone coincides with a strong increase in T3 and TR
mRNA concentrations in the brain. During this time the fetal hypothalamus already shows
evidence for TH signaling. Expression of components crucial for central TH signaling show
a specific developmental timing in the human hypothalamus. A coordinated expression
of deiodinases in combination with TH transporters suggests that TH concentrations are
regulated to prevent untimely maturation of brain cells. Even though the fetus depends on
the maternal TH supply, there is evidence suggesting a role for the fetal hypothalamus in
the regulation of TH serum concentrations. A decrease in expression of proteins involved
in TH signaling towards the end of pregnancy may indicate a lower fetal TH demand. This
may be relevant for the thyrotropin (TSH) surge that is usually observed after birth, and
supports a role for the hypothalamus in the regulation of TH concentrations during the
fetal period anticipating birth.
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INTRODUCTION
Thyroid hormone (TH) is crucial for normal fetal growth
and maturation including the brain (Eayrs and Taylor, 1951;
Morreale de Escobar et al., 1983; Legrand, 1984). Developmental
TH deficiency impairs growth, and compromises adaptation
to life outside the womb (Forhead et al., 1998; Hillman
et al., 2012; Sferruzzi-Perri et al., 2013; Forhead and Fowden,
2014). The importance of TH during development is widely
recognized and reflected in government interventions, such
as iodine supplementation programs, as recommended by the
World Health Organization (e.g., universal salt iodisation),
and population wide screening for TH deficiency via the
heel prick (Ford and LaFranchi, 2014). TH deficiency
during development causes irreversible damage, which
can largely be prevented by TH replacement therapy
(Dubuis et al., 1996; Grüters and Krude, 2011).
During uterine development the fetus is largely dependent
on the maternal TH supply, and TH receptors (TRs) are
already present before the thyroid gland becomes functional
(Morreale de Escobar et al., 2004, 2007). TH is implicated
in many developmental processes in the brain including
cell cycling, synaptogenesis, migration, plasticity, and
myelination (Bernal, 2007). In both humans and rodents,
brain development is not completed at, and continues after
birth. From the moment of birth, the offspring no longer
benefits from maternal TH supply. Insufficient TH availability,
also during the postnatal developmental period, leads to
severe neurological damage and mental retardation. TH
insufficiency can be the result of iodine deficiency, or of
defective formation of the thyroid gland (Deladoëy et al.,
2007; Nilsson and Fagman, 2013; Szinnai, 2014). Interestingly,
many studies have focused on the importance of TH in
brain development, but much less is known about the
development of the hypothalamic feedback loop of TH.
When studying intrauterine development, it is not only
the fetal hypothalamus that is in play, it is also that of the
mother. In view of the cross-talk between systems it is often
not possible to distinguish between the different (neuro-
)endocrine systems in play. Rodent studies have been crucial
for understanding TH signaling, but the research is complicated
by interspecies differences that are observed between rodents,
humans and other mammals. In the present review I will
focus mainly on TH signaling in the developing human
hypothalamus.
TH SIGNALING IN THE HYPOTHALAMUS
Under normal conditions, TH signaling is controlled via a
classic negative feedback pathway at the level of the anterior
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FIGURE 1 | (A) Classic thyroid hormone (TH) feedback loop. TH exerts a
negative feedback at the level of the hypothalamus and anterior pituitary.
(B) Model for thyroid hormone (TH) transport and metabolism in the human
hypothalamus. The model indicates distinct roles for the different TH
transporters in hypothalamic TH action by affecting intracellular TH
concentrations through import and efflux. T2 = 3,3′-T2 (Adapted from
Alkemade et al., 2011).
pituitary and hypothalamus (Figure 1A). Hypothalamic TH
signaling is also involved in circadian rhythmicity, feeding
and adaptation to environmental challenges (Costa-e-Sousa
and Hollenberg, 2012). Interestingly, studies in anencephalic
humans have shown that when the hypothalamus is not
formed at all, pituitary-thyroid function still develops (Beck-
Peccoz et al., 1992). Following normal brain development,
hypophysiotropic neurons of the paraventricular nucleus (PVN)
of the hypothalamus expressing thyrotropin releasing hormone
(TRH) project to the portal system, via which it reaches the
thyrotropin (TSH) producing cells of the anterior pituitary.
TSH, which is subsequently released, binds to its receptor
in the thyroid where TH is produced and released. TH is
released predominantly as thyroxine (T4), a prohormone, and
to a lesser extent as the active 3,3′,5-triiodothyronine (T3).
T4 is converted locally into T3 providing a negative feedback
at the level of the pituitary as well as the hypothalamus
(Figure 1A). T3 mainly acts by regulation of gene expression
via binding of nuclear TRs, although nongenomic effects of T3
have been described as well (Cheng et al., 2010; Davis et al.,
2013).
A number of specific proteins are required for normal
TH signaling in the brain including the hypothalamus. These
proteins have been studied mainly in humans and rodents.
TH cannot enter or exit the cell via passive diffusion and
requires facilitated transport across the cell membrane, as well
as the membrane of the cell nucleus (Visser et al., 2008;
Heuer and Visser, 2009; Wirth et al., 2014). Proteins capable of
transporting TH belong to a number of families including the
sodium dependent organic anion tranporters (NTCP), organic
anion transporting polypeptides (OATP), heterodimeric amino
acid transporters (HAT) including light chains LAT1 and 2,
and the monocarboxylate transporters MCT8 and 10 (Friesema
et al., 1999, 2001; Hennemann et al., 2001; Roberts et al.,
2008). The distribution patterns of these transporters throughout
the body show significant overlap, and most of them are
able to transport other molecules than iodothyronines as well.
MCT8 appears to be specific for transporting iodothyronines
(Friesema et al., 2003). OATP1C1 is expressed in endothelial
cells of the blood brain barrier, as well as the choroid
plexus (Roberts et al., 2008). MCT8 is also expressed in the
human as well as the rodent choroid plexus (Heuer et al.,
2005; Friesema et al., 2012). LAT1 and 2 do not appear
to play any major role in the human brain (Wirth et al.,
2014).
T4 is converted to T3 via intracellular outer ring deiodination.
In the central nervous system conversion of T4 into T3 is mainly
dependent on type 2 deiodinase (D2), and inactivation of T4
and T3 is dependent on inner ring deiodination by type 3
deiodinase (D3). Type 1 deiodinase (D1) does not appear to
play a major role in rodent or human brain (Bianco et al.,
2002). Interestingly, D2 is mainly expressed in glial cells of the
hypothalamus. These include astrocytes and specialized glial cells
called tanycytes, which are located at the ependymal layer of the
third ventricle (Tu et al., 1997; Alkemade et al., 2005a). Dio2
mRNA expression in tanycytes shows a clear increase in response
to hypothyroidism and iodine deficiency (Tu et al., 1997; Peeters
et al., 2001).
In the cell nucleus, T3 binds the nuclear receptors encoded
by the THRA and THRB genes, which give rise to TRα1, α2, β1
and β2 (Sap et al., 1986; Weinberger et al., 1986; Benbrook and
Pfahl, 1987; König and Moura Neto, 2002). TRα2 does not bind
T3, but exerts dominant negative effects on TRH transcription
(Guissouma et al., 2014). Studies in knockout mice indicate that
TRβ2 is crucial for the negative feedback loop controlling TH
concentrations in the body (Abel et al., 2001). In addition, TRβ1
is also involved in regulating serum TSH (Guissouma et al., 2006).
It is not entirely clear what the role for TRα in the negative
feedback loop is. In the human and rat hypothalamus TRs are
expressed in a number of nuclei, including the PVN where the
hypophysiotropic TRH neurons are located (Lechan et al., 1994;
Alkemade et al., 2005b). We, and others have proposed models for
TH signaling in the hypothalamus, which involves both glial cells
and neurons (Guadaño-Ferraz et al., 1997; Tu et al., 1997; Diano
et al., 2003; Lechan and Fekete, 2004; Alkemade et al., 2005a;
Figure 1B).
Hypothalamic TH signaling extends beyond the classical
feedback loop affecting the TRH neurons of the PVN. In
addition, functioning of other nuclear receptors such as the
liver X receptor is dependent on thyroid status (Ghaddab-
Zroud et al., 2014). We found in our previous studies on
the human hypothalamus that the individual TR isoforms
are expressed in a number of hypothalamic nuclei and
studies in rats have shown comparable results. In addition,
the supraoptic (SON), infundibular (IFN), tuberomamillary
(TMN), and the lateral tuberal nucleus (NTL) express TRs.
In rodents, TR isoforms have been described in the arcuate
nucleus (ARC), the rodent equivalent of the IFN, as well
as SON and PVN (Bradley et al., 1989; Cook et al., 1992;
Lechan et al., 1994). The SON showed higher TRα than
TRβ expression (Bradley et al., 1989). Studies in a transgenic
mouse line with a GFP-labeled TRα1 (Wallis et al., 2010)
have shown that the distribution of the TRα1 is even more
widespread than we concluded from our studies on the human
hypothalamus. In mice TRα1 was expressed in the majority
of cerebral neurons, including many hypothalamic nuclei, as
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well as in tanycytes. Several explanations are possible for the
discrepancy between our findings and findings in this transgenic
mouse strain. It is possible that the antibodies we used for
studying TR expression in the human hypothalamus lacked
sensitivity to detect all TRs in the human hypothalamus, or,
alternatively, interspecies differences may exist. Wallis et al.
(2010) further showed TRα1 expression in nonneuronal cells
including hypothalamic oligodendrocytes. In our earlier studies
in humans we did not report on oligodendritic expression
of TRs (Alkemade et al., 2005b). Interestingly, the absence
of a functional MCT8 results a persistent hypomyelination
in humans (López-Espíndola et al., 2014). The findings by
Wallis et al. fit with the ubiquitous expression of the TH
transporter OATP1C1 throughout the human hypothalamus,
in both neurons as well as glial cells (Alkemade et al., 2011).
In rodents Oatp1C1 does not show neuronal expression in
the hypothalamus (Roberts et al., 2008). It is possible that
other TH transporters are involved in the transport of TH
in and out of TRα1 expressing neurons and glia in rodents.
In addition, we have shown that MCT8 is expressed in
both neurons and glial cells of the human hypothalamus.
Interestingly, in humans MCT10 expression was confined to
neurons in the majority of hypothalamic nuclei. The distinct
distribution patterns support different roles for the individual TH
transporters.
TH SIGNALING IN THE DEVELOPING HUMAN
HYPOTHALAMUS
Very few studies have investigated the distribution of protein
expression in the developing human hypothalamus, therefore,
little is known about its chemoarchitecture. Human brain
material obtained is not readily available, and tissue from
embryo’s, fetuses and children is even scarcer. Koutcherov
et al. (2002), studied 33 human hypothalamic specimens
ranging in age from 9 weeks of gestation to 3 weeks after
term birth. This study describes the development of human
hypothalamic zones and individual nuclei and provides
a clear schematic representation of the development of
the human hypothalamus. Hypothalamic differentiation
starts already during the first trimester of pregnancy. The
lateral zone is the first zone to differentiate, and gives rise
to the lateral hypothalamus (LH), Posterior hypothalamic
area (PH), lateral tuberal hypothalamic nucleus (LTu) and
perifornical hypothalamic nucleus (PeF). The core zone
consists of a heterogeneous collection of nuclei positioned
between the LH and midline structure, including medial
preoptic nucleus (MPO), ventromedial nucleus (VMH),
supramamillary nucleus (SUM) and mammillary bodies
(Mb). The midline hypothalamus consists of structures
differentiating in close proximity of the ventricular wall,
including the suprachiasmatic nucleus (SCN), IFN, PVN
and SON. These structures become evident during late
gestation.
We have described the developmental expression of proteins
involved in TH signaling in 15 fetal and infant human
hypothalami obtained at various stages of development (Friesema
et al., 2012). To my knowledge comparable studies investigating
fetal functional neuroanatomy underlying TH signaling are
not available for rodents. In our study on the developing
human hypothalamus the first sampling point was at 17
weeks of gestation. Although we did not study TR expression
in our human brain specimens, at this time both TRs and
the ligand T3 have been reported in the human brain and
TR mRNA increases strongly from 10–18 weeks gestation
(Iskaros et al., 2000). Interestingly, during development TRα1
is not expressed in the ventricular zone in mice where neurons
are born and proliferate (Wallis et al., 2010). These studies
showed that TRα1 appears to be expressed in immature
neurons, preceding the expression of NeuN. The TRα1 expression
increases when cells reach their destination and differentiate.
This means that TRα1 acts after cell cycle exit. The specific
oligodendrocytic expression of TRα1 fits with data showing that
oligodendrocyte precursors differentiate after T3 activation of
a transiently expressed TR (Billon et al., 2002). This indicates
that in mice TRα1 expression is required only during a specific
time window in development (Wallis et al., 2010). Whether a
similar pattern is also present in the (human) hypothalamus is
unknown.
At 17 weeks of gestation the mamillary bodies become
prominent and the LH, SON and IFN can already be
distinguished, as well as the fornix and the anlage of the
PVN (Koutcherov et al., 2002). In our human studies, we
observed some MCT8 expression in blood vessels at 17 weeks,
indicating possible presence of TH signaling (Friesema et al.,
2012). We only observed few D3 positive neurons in the
IFN, whereas D2 did not show any staining. These findings
indicate T3 degradation, but not production in the human fetal
hypothalamus at this moment in development. This is in line
with the prevention of TH exposure during early stages of brain
development, which may cause untimely maturation of brain
cells as observed in rodents (Obregon et al., 2007). Interestingly,
excess TH as a result of deletion of the Dio3 gene in mice
results in premature cerebellar differentiation, as well as a central
hypothyroidism associated with defective TRH regulation, which
persists throughout life (Hernandez et al., 2006, 2007; Peeters
et al., 2013).
At 18 weeks gestation all T3 in the brain is produced via
local deiodination (Ferreiro et al., 1988), which fits with D2
activity and T3 content in the cerebral cortex during the second
trimester (Kester et al., 2004). At this time TH transporters are
also expressed in the cerebral cortex (Chan et al., 2014). It does
not appear that at this time point the human hypothalamus
is capable of converting T4 into T3. This finding could reflect
timing differences between distinct brain areas. At 18–23 weeks
of gestation the PVN develops, and the PeF area as well as
the LH become discernable. At the end of this period the
SCN becomes visible (Koutcherov et al., 2002). At present no
data are available on TH signaling at this time-point during
development.
At 24–33 weeks the fetal human hypothalamus takes and adult
like appearance. At 25 5/7 weeks, we found MCT8 expression in
the PVN and IFN, which should now also express Neuropeptide
Y (Koutcherov et al., 2002). In addition, MCT8 neurons showed
a scattered pattern throughout the hypothalamus, as well as
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in tanycytes and blood vessels (Friesema et al., 2012). MCT10
showed expression in SON, PVN and IFN. D3 and OATP1C1
were also expressed in the IFN. At this time D2 was still very
low and only found surrounding blood vessels. At 27 weeks
MCT8 expression in PVN and LH persisted, and MCT10
showed more widespread expression in PVN, LH and SON.
OATP1C1 was also present in LH, PVN and IFN. Hardly any
D2 was observed, whereas the PVN showed prominent D3
expression.
At 27 2/7 weeks of gestation TH signaling appeared
to increase. MCT8 was present in neurons of the PVN,
IFN and LH, as well as in tanycytes. MCT10 was strongly
expressed in the LH, as well as in neurons of the IFN,
PVN and SON. OATP1C1 was present in blood vessels of
the organum vasculosum laminae terminalis (OVLT) and in
LH, IFN, PVN and SON neurons. D2 at this stage showed
expression in tanycytes. In addition D2 staining surrounded
blood vessels of the OVLT. Now D3 expression was not observed
(Friesema et al., 2012). It is possible that the absence of
D3 expression indicates an increased need for TH at this
stage of development persisting to late gestation, after which
TH signaling appears to decrease again. At 28 3/7 weeks
gestation MCT8 staining was present in the IFN, PVN and
LH. MCT10 and OATP1C1 also showed expression in the LH.
In addition, OATP1C1 was also present in the IFN and in
tanycytes, which also expressed D2. Again D3 showed very little
expression.
From 34 weeks gestation term gestation, the NTL and TMN
can develop further (Koutcherov et al., 2002). At 34 5/7 weeks
the expression of all tested TH transporters was low. What is
interesting to note, is that during late gestation (35 weeks), D2,
MCT8 and OATP1C1 expression was very weak, and MCT10
expression was not observed. This was in contrast to the strong D3
expression observed in the IFN, TMN and LH. These observations
led us to speculate that these observations may be related to
the TSH surge observed in humans associated with birth, and
that the hypothalamus may play a role in giving rise to this
TSH surge. Although highly speculative, decreased T3 availability
due to decreased outer ring deiodination and TH transport,
together with increased inner ring deiodination by D3 could lead
to upregulation of TRH, which is negatively regulated by T3.
A very similar staining pattern was observed in hypothalami of
children that were born at term. Inverse hypothalamic expression
levels of D2 and 3 have also been observed in birds and
mammals in the context of photoperiod setpoints (Watanabe
et al., 2007).
At 2 months of age staining for MCT8 in SON, PVN,
and in the lining of the third ventricle was found in
humans. MCT10 immunoreactivity was present in SON and
PVN. Sporadic expression was found in the LH. OATP1C1
showed a more scattered pattern and increased staining was
observed in SON, PVN, TMN, IFN and the ependymal
layer. D2 expression was present in blood vessels. D3 showed
expression in PVN as well as other hypothalamic nuclei.
In children aged 20–29 months of age, we found moderate
MCT8 and moderate to strong MCT10 staining in PVN,
SON, IFN and weak staining in the LH. OATP1C1 was
present in PVN, SON, IFN and in some cells in the
ependymal layer of the third ventricle. In addition, scattered
OATP1C1 positive cells were present, as well as staining
in NTL, TMN, SCN and LH. D2 was expressed in blood
vessels especially in the IFN and in tanycytes. At this
time point stainings very much resembled our observations
in the adult hypothalamus (Alkemade et al., 2005a, 2011;
Figure 2).
Hypothalamic expression patterns throughout the
developmental period studied are summarized in Figure 3.
This figure indicates that regulation of proteins involved in TH
signaling may play an important role in timing of TH availability
at different stages of development.
DEFECTIVE HYPOTHALAMIC TH SIGNALING
Defects in proteins involved in hypothalamic TH signaling
are potentially reflected in alterations in serum TH and TSH
concentrations. A number of mutations in, TRs and TH
transporters has been described. These syndromes are described
excellently in a recent review (Dumitrescu and Refetoff, 2013),
and here only findings relevant for HPT-axis regulation and the
brain are recapitulated.
TRs
Complete deletion of all TRs in mice causes serum TSH levels
that are 500-fold higher than those of the WT mice, and T4
concentrations 12-fold above the average normal mean (Gauthier
et al., 1999). In humans both mutations in the THRA and THRB
genes have been reported.
RESISTANCE TO THα
The first subject described suffering from Resistance to THα
(RTHα), was diagnosed only recently (Bochukova et al., 2012).
RTHα is caused by a mutation in the THRA gene, which
encodes TRα1 and α2. The mutation caused a truncation of
the protein, which lacked the C-terminal α-helix. This 6-year
old girl showed low-normal or subnormal levels of total T4
and free T4, high-normal or elevated levels of total T3 and
free T3, in addition to normal levels of TSH (Bochukova et al.,
2012). Since the description of this young girl, additional patients
with RTHα have been described in literature. RTHα patients
show cognitive impairment and macrocephaly (Bochukova et al.,
2012; van Mullem et al., 2013). In addition, the phenotype
observed in a patient with mutations both in TRα1 and α2 was
very similar (Moran et al., 2014). Serum TH concentrations do
not suggest any major impairment of the classic hypothalamic
feedback system. This is corroborated by findings in mice. Mouse
models with a mutant TRα1, show a range of phenotypes,
dependent on the specific mutation or deletion. Brain changes
have been described as well (Wallis et al., 2008; Mittag et al.,
2010), and changes resulting from defects in the autonomic
nervous system including impaired cardiovascular response to
stress, activity and environmental temperature changes. The
hypothalamus has only been studied in detail in one of these
mouse models, showing the absence of a parvalbumin positive
neuronal population in the anterior hypothalamic area with
consequences for the regulation of the cardiovascular system
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FIGURE 2 | Adult appearance of the human hypothalamus. Gray areas
indicate sites of TR isoform expression. Upper panels: rostral level; lower
panels: caudal level. III, Third ventricle; AC, anterior commissure; BST, bed
nucleus of the stria terminalis; DBB, diagonal band of Broca; FO, fornix; LV,
lateral ventricle; NTL, nucleus tuberalis lateralis; OC, optic chiasm; OT, optic
tract; SCN, suprachiasmatic nucleus; SDN, sexually dimorphic nucleus; SON,
supraoptic nucleus; TMN, tuberomammilary nucleus (Taken from Alkemade
et al., 2005b).
(Mittag et al., 2013). The HPA-axis was not affected in these
mutant mice as assessed by hypothalamic corticotropin releasing
hormone (CRH) and pro-opiomelanocortin (POMC) expression
(Mittag et al., 2010).
RESISTANCE TO THβ
Patients harboring mutations in the TRβ1 show more
pronounced changes in serum TH concentrations. For the
THRB gene number of mutation hotspots have been defined
(Dumitrescu and Refetoff, 2013). Characteristic are elevated
freeT4 levels, and to a lesser extent T3. In addition, TSH is
normal or slightly increased, and responsive to TRH. Patients
generally do not display the usual metabolic symptoms associated
with hyperthyroidism, although they often present with goiter
(Refetoff et al., 1993). TRβ2 knockout mice show a severe
disruption of the hypothalamic TH feedback system (Abel et al.,
2001).
TH TRANSPORTERS
In MCT8 deficient subjects serum TSH is modestly increased,
which fits with the decreased serum T4 concentration but not
with the elevated serum T3 level. Since MCT8 is expressed in
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FIGURE 3 | Schematic representation of (A) D2 expression in the human
infundibular nucleus/median eminence and periventricular area, D3
expression in the paraventricular nucleus (PVN) and (B) TH transporter
expression throughout PVN development. Note the opposite expression
pattern of D3 vs. TH transporters and D2 expression (Taken from Friesema
et al., 2012).
the hypothalamus and pituitary, it is likely that inactivation
of the gene interferes with the negative feedback at the level
of the hypothalamus (Fliers et al., 2006). In addition, defects
in brain development have been described in patients lacking
MCT8 (López-Espíndola et al., 2014). Rodent models for
MCT8 mutations do not reproduce the severe psychomotor
phenotype observed in humans, but do faithfully reproduce
the biochemical phenotype (Trajkovic et al., 2007). In Mct8KO
mice, hypothalamic TRH expression is markedly increased
and high T3 doses are needed to suppress it. In humans
there is clear expression of MCT10 and OATP1C1 already
in the second trimester of pregnancy. The presence of these
transporters is does compensate for the absence of MCT8 as
evidenced by the neurological defects observed in patients lacking
MCT8. Wirth et al. suggest that Lat2 might compensate for
the Mct8 deletion in mice. This is unlikely in humans, since
developing neurons in the human brain only show very low LAT2
expression (Wirth et al., 2009). It is possible that in rodents
other transporter variants such as Oatp1a4 and Oatp1a5 may
further compensate for MCT8 defects. These transporters appear
not to have orthologs in the human brain (Suzuki and Abe,
2008).
TH CONVERSION DEFECTS
Selenocysteine insertion sequence (SECIS) binding protein 2
(SBP2) plays an important role in insertion of selenocysteine
into selenoproteins such as deidonases. Defects in the
SBP2 gene therefore interfere with the production of these
conversion enzymes, resulting in high T4 and rT3, low T3,
normal or slightly elevated TSH concentrations (Dumitrescu
et al., 2005). Genetic variants in DIO2 in humans do not
show any clear phenotypic changes (Zevenbergen et al.,
2014).
CONCLUSION
TH signaling involves facilitated transport, local conversion
and receptor binding. TH signaling is therefore dependent on a
number of proteins, each of which can become defective, thereby
affecting a plethora of processes modulated by TH. The effects
of mutations in TH signaling on the functional neuroanatomy,
Frontiers in Neuroanatomy www.frontiersin.org February 2015 | Volume 9 | Article 15 | 6
Alkemade Thyroid hormone and the developing hypothalamus
which underlies the classic negative feedback of TH on the
hypothalamus is dependent on the affected gene, the type of
mutation, as well as the compensatory mechanisms, which appear
to differ between species. These effects are largely assessed by
evaluation of biochemical parameters. Detailed studies on the
functional neuroanatomy underlying hypothalamic TH signaling
are scarce, and are complicated by interspecies differences, as
well as the limited availability of human postmortem brain
material for research purposes. Future studies on the expression
of TR isoforms in the developing (human) hypothalamus would
strongly improve our understanding of central TH signaling
during development.
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